REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.22
Ask: 6.50
Change: 0.00 (0.00%)
Spread: 1.28 (24.521%)
Open: 5.76
High: 5.76
Low: 5.76
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results

Fri, 23rd Dec 2022 17:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

SulNOx Group PLC - London-based green technology company - Raises around GBP760,000 via placing and subscription of new shares at 11.5 pence price. Says largest shareholder Nistad AS invests further GBP80,000 to hold 13% in equity at SulNox. Follows announcement from yesterday which proposed fundraise to raise a minimum of GBP750,0000. "Despite difficult market conditions, we are pleased to have received institutional investor backing for SulNOx as an ESG, energy transition company with tremendous potential from reducing fossil fuel consumption and emissions across the globe," says Chief Executive Officer Ben Richardson. "Following the fundraising, SulNOx will have a runway to deliver increasing revenues and be able to accelerate our growth plans through 2023."

----------

Cindrigo Holdings Ltd - London-based clean energy producer - Reaches agreement with Danir AB, its largest shareholder and creditor, to provide new funding and restructure short-term debt of GBP4.3 million into long-term convertible loans. Danir provides additional loan funding of GBP750,000, following BK Fortuna AS's reported failure to provide agreed funding to Cindrigo, as announced on September 30. Says additional Danir funding is via 24-month convertible loan with a 5% interest rate per year. Says this loan is convertible into Cindrigo shares from 60 days after the company is readmitted to listing, with conversion price equal to the higher of either a 25% discount to the 30-day volume-weighted average share price or the minimum price per share of 125 pence. Existing GBP3.8m debt funding from Danir will be restructured and replaced by issue of new 10-year zero coupon convertible loan notes with a conversion price of 15p per share. Can be converted for a maximum of 25.3 million new Cindrigo shares.

----------

Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 trial in the European Respiratory Journal Open Research. Says while Sprinter trial does not meet the primary endpoints of discharge from the hospital and recovery, there is an encouraging signal in reduction in the relative risk of progression to severe disease or death with 35 days. Says SNG001 is well tolerated, as shown in previous clinical trials. Chief Scientific Officer & Lead Author Phillip Monk says: "The results from the SG016 phase 2 and the Sprinter trial of SNG001 in hospitalised patients, and the Activ-2 trial in the home setting, suggest that SNG001 may be preventing progression to severe disease. With these data, we remain confident in the potential of SNG001 as a broad-spectrum antiviral for high-risk patient populations infected with respiratory viruses including influenza and RSV and are focused on its continued clinical development." Says SNG001 is not approved for use anywhere in the world.

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Says it expects to achieve an average gross daily production rate of around 90 million standard cubic feet per day for 2022, compared to previous guidance of between 75MMscf/d and 85MMscf/d. As of Monday, current production levels are steady at a supply-constrained 90MMscf/d, below current demand nominations of 95MMscf/d from its key offtaker the Tanzania Petroleum Development Corp. Says Mnazi Bay joint venture is undertaking an infield workover and perforation programme, aiming to meet gas demand nominations in 2023. Hopes production levels will reach 90MMscf/d from late 2024 until at least 2027. Cash is USD30.0 million on December 1, while joint venture capital expenditure budget for 2023 is USD13.5 million.

----------

SEEEN PLC - London-based media and technology platform - Raises around GBP2.6 million via open offer of 523,887 shares. Says net proceeds are intended to bolster company's sales and marketing team, alongside investing into technology development projects to support planned next stage of growth.

----------

Dolphin Capital Investors Ltd - Cardiff, Wales-based investor in high-end resort developments in the eastern Mediterranean - Completes the EUR17.9 million disposal of its entire interest in the One&Only at Kea Island project. Prior to sale, Dolphin was 67% owner of Single Purpose Vehicle Ten Ltd, which owned 50% of OOKI, giving Dolphin Capital an effective 33% equity interest in OOKI. Receives EUR900,000 of sale proceeds on December 5 as an advance payment. Receives the remaining EUR17.0 million balance on completion. Around EUR13.0 million of the disposal proceeds used to repay its existing loan facility by December 31, which Dolphin Capital drew down in June and July. Says all debt has now been fully repaid.

----------

Curtis Banks Group PLC - Bristol-based financial services company - Says Nucleus Financial Platforms Ltd completes its due diligence amid advanced discussions over a possible offer for the entire share capital of Curtis Banks. Says both parties are close to agreeing transaction. Extends deadline for nucleus to announce offer to January 9 from Friday. Follows announcement of a potential takeover on November 25.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
5 Dec 2012 11:10

Synairgen reports 'significant progress'

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote

Read more
18 Jul 2012 09:39

Synairgen raises 2.5m pounds from placing

Synairgen, a Southampton-based research firm, has placed around 5.56m shares at 45p each, enabling the firm to progress with its primary programme following the successful clinical trial results of an asthma treatment product. The placing has raised £2.5m before expenses. In a related transaction,

Read more
19 Apr 2012 10:22

Synairgen no wheeze as asthma drug trial boosts shares

Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections. The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the caus

Read more
29 Jan 2011 14:04

Takeover targets named

Hold on tight, a wave of patent expiries and generic competition could spark another round of consolidation in the pharma and medical devices sector this year. Billions of dollars have been spent on takeovers or pumped into new issues in recent months as confidence in the recovery grows and cash-ri

Read more
29 Jul 2010 12:51

Small caps round-up: Plantic Technologies, Acal, Anglesey

Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors. Acal, which provides technology products and services across Europe and South Africa, said underlying sales

Read more
29 Jul 2010 07:56

Synairgen FY Net Loss GBP2.6M Vs Loss GBP2.5M

LONDON (Dow Jones)--Synairgen PLC (SNG.LN), a respiratory drug discovery and development company with a particular focus on viral defense, Thursday reported a full year net loss of GBP2.6 million, compared with a loss of GBP2.5 million the previous year. MAIN FACTS: -Research and development

Read more
17 May 2010 13:02

Small caps: Cove Energy, Synairgen, Wilmington...

PR specialist Freshwater cut the dividend as profits fell to £32,000 from £106,000 in the six months to end February. Revenues fell to £3.66m from £4.51m. "While the economic environment remains challenging, Freshwater is seeing greater stability and growth potential in most of its markets. Alongsi

Read more
6 May 2010 12:49

Small caps round-up: Griffin Mining, Energy XXI

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008. The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $2

Read more
9 Nov 2009 16:31

London close: Miners power Footsie gains

Mining stocks were at the vanguard of a strong advance from FTSE 100 as commodity prices were boosted by plans outlined by world leaders over the weekend to continue with stimulus measures. Kazakhmys, Fresnillo, Rio Tinto and Vedanta were some of the best performers in the mining sector. Mining g

Read more
9 Nov 2009 14:23

London afternoon: Cadbury rejects Kraft bid

After all the waiting and speculation, the formal bid for Cadbury from US group Kraft Foods proved a disappointment, but it has not dampened sentiment in a buoyant London market. Kraft formally announced a bid for Cadbury on the same terms as the indicative offer announced at the beginning of Septe

Read more
9 Nov 2009 08:42

Synairgen hails swine flu result

The share price of respiratory disease drug developer Synairgen more than doubled in early trading on Monday after positive developments for its inhaled interferon beta programme. Laboratory experiments confirmed the antiviral potency of IFN-beta against 2009 H1N1, better known as ‘swine flu’. The

Read more
27 May 2009 07:59

Small caps round-up: LonZim, Lees Foods, blinkx ...

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28. The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel se

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.